ClinicalTrials.gg
RecruitingNCT07457463FILIPUpdated Mar 9, 2026

Evaluation of the Pulmonary Fibrosis Learning and Self-management Programme (FILIP)

An interventional study of Blended patient education and self-management programme in Lung Fibrosis Interstitial, sponsored by Insel Gruppe AG, University Hospital Bern. Recruiting at 2 sites in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-09.

Sponsored by Insel Gruppe AG, University Hospital Bern · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Oct 2025, registered Jan 2026).
  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this observational study is to evaluate the feasibility and acceptability of a newly developed digital education and self-management program for people with fibrotic interstitial lung diseases (FILD) during inpatient pulmonary rehabilitation and outpatient interstitial lung disease (ILD) care. The study also explores whether participation in the program is associated with changes in health-related outcomes.

The main questions this study aims to answer are:

  • Is the digital education and self-management program acceptable, useful, and practical for patients with FILD?
  • Is it feasible to recruit and retain patients and to collect outcome data for a future larger effectiveness study?
  • Do patients who participate in the program show differences in health-related outcomes compared with patients treated before the program was implemented?

Patients who consent to participate during the implementation phase will be offered access to the digital education and self-management program. Their outcomes will be compared with those of a historical cohort of patients who received usual care before the program was introduced.

Participants will:

  • Use a web-based digital education and self-management program with multiple e-learning modules tailored to individual needs and preferences
  • Access the program via smartphone, tablet, or computer during inpatient rehabilitation or outpatient care
  • Discuss questions related to the program content with healthcare professionals during routine rehabilitation sessions or clinic visits
  • Complete questionnaires about their experience with the program and their health-related outcomes
Read the detailed description

Fibrotic interstitial lung diseases (FILD) are a group of rare and chronic lung conditions that are often associated with persistent symptoms, reduced quality of life, and limitations in daily activities. People living with FILD frequently report unmet needs regarding disease-specific education and support for self-management. In particular, patients identify a lack of clear, understandable, and patient-centered educational resources as a major gap in current inpatient rehabilitation and outpatient interstitial lung disease (ILD) care.

To address this need, a blended digital education and self-management program was developed for patients with FILD. The program combines web-based e-learning modules with opportunities for discussion and clarification with healthcare professionals during routine inpatient rehabilitation or outpatient clinical care. The digital content addresses core and optional topics related to disease understanding, symptom management, and self-management strategies. Suggested modules are based on individual patient needs and preferences identified through initial questions within the digital platform, while all modules remain accessible to all users.

This study is an exploratory, multicenter, before-after observational cohort study with an embedded feasibility sub-study. Two cohorts are included: a historical control cohort consisting of patients treated before implementation of the digital program, and a feasibility cohort consisting of patients treated after implementation who consent to participate and receive access to the digital education and self-management program. Participants are not randomized, and investigators do not assign patients to intervention or control groups. Exposure to the program is determined by timing of implementation and patient consent.

The primary objective of the feasibility sub-study is to assess intervention feasibility, including acceptability, perceived usefulness, patient satisfaction, and adherence to the digital program. Adherence is assessed by documenting participation in and completion of the educational modules. Semi-structured interviews with patients and healthcare professionals are conducted to explore barriers and facilitators to implementation in inpatient rehabilitation and outpatient care settings.

Secondary objectives address study feasibility for a future larger effectiveness trial. These objectives include evaluating the feasibility of recruiting the targeted number of participants, retaining participants through follow-up assessments, and collecting health-related outcome data with minimal missing data.

Health-related outcomes are collected to explore patients' responsiveness to the digital education and self-management program and to inform the design of a future effectiveness trial. The primary health-related outcome is self-efficacy, assessed at multiple time points using a pulmonary rehabilitation-adapted self-efficacy measure. Secondary health-related outcomes include health-related quality of life, assessed using a disease-specific questionnaire for interstitial lung disease, as well as changes in self-efficacy at earlier follow-up time points.

Additional exploratory outcomes include functional exercise capacity derived from routinely collected clinical data, patient-reported symptoms and health status using visual analog scales, patient-reported respiratory symptoms, psychological well-being, and supplemental oxygen requirements during activity. These outcomes are collected to provide a comprehensive picture of patient experiences and to evaluate the feasibility and relevance of these measures for future studies.

The digital education and self-management program is delivered through a web-based learning management system and can be accessed via smartphone, tablet, or desktop computer. For inpatient rehabilitation patients, access is provided during the rehabilitation stay, with flexible use throughout the program and support from therapists as needed. Topics from the digital program can be discussed during routine therapy sessions, and patients retain access to the digital resources after discharge. For outpatient care patients, access is provided during an ILD clinic visit, with opportunities to discuss program content during follow-up appointments and reminders to encourage engagement.

Overall, this study aims to generate essential information on the feasibility and acceptability of implementing a digital education and self-management program for patients with FILD, while providing preliminary data on relevant health-related outcomes to support planning of a future multicenter effectiveness trial.

02

Conditions studied

  • Lung Fibrosis Interstitial

Browse trials for

Keywords

  • self-management
  • patient education
  • self-efficacy
  • blended learning
  • lung fibrosis
  • ILD
  • digital patient information
03

In context

Pulmonary Fibrosis

342 studies on the registry are indexed under Pulmonary Fibrosis; 98 are open to participants now.

This study's planned enrollment of 80 is above the median of 59 across 212 interventional studies indexed under Pulmonary Fibrosis.

Browse Pulmonary Fibrosis studies →

Lead sponsor

Insel Gruppe AG, University Hospital Bern is the lead sponsor of 744 studies on the registry; 182 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of a FILD as major indication for pulmonary rehabilitation (for Berner Reha Zentrum only)
  • Enrolled in Idiopathic interstitial Pneumonia (IIP) cohort study (Nr. 246/15 / PB_2016-01524) and agreed to further use of data for further research purpose (for Inselspital only)
  • Age ≥ 18 years
  • Written

Exclusion criteria

Exclusion criteria are:

  • Cognitive inability or insufficient knowledge of project language (German) to follow or study procedures
  • Sarcoidosis
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Intervention group

    This arm includes patients with fibrotic interstitial lung diseases enrolled in the observational study during the feasibility phase. Participants who consent to participate are offered access to a blended digital education and self-management program in addition to usual inpatient pulmonary rehabilitation or outpatient ILD care.

    Behavioral: Blended patient education and self-management programme

Interventions

  • BehavioralBlended patient education and self-management programme

    The program consists of multiple web-based e-learning modules covering core and optional topics relevant to lung fibrosis. Modules are suggested based on individual symptoms and self-management needs, but all content is accessible to all users. The program can be accessed via smartphone, tablet, or computer using a web link. It is intended solely for education and well-being support and is not used for diagnosis, monitoring, treatment, or prognosis of disease. In inpatient rehabilitation, patients may use the program flexibly during their stay, with support from therapists as needed, and can discuss content during routine therapy sessions. In outpatient care, patients receive access during an ILD clinic visit and can discuss content during follow-up appointments, supported by reminders to encourage use.

06

What researchers measure

Primary outcomes

  1. Intervention feasibility outcomes - Acceptance

    Acceptability of Intervention Measure (AIM): 4-item questioniare measuring the acceptability of an intervention on a 5-likert scale (completely disagree to completely agree).

    Time frame: 3-6 months follow-up

  2. Intervention feasibility outcomes - Appropriateness

    Intervention Appropriateness Measure (IAM): 4-item questioniare measuring the appropriation of an intervention on a 5-likert scale (completely disagree to completely agree).

    Time frame: 3-6 months follow-up

  3. Intervention feasibility outcomes - Feasibiilty

    Feasibility of Intervention Measure (FIM): 4-item questioniare measuring the acceptability of an intervention on a f-likert scale (completely disagree to completely agree).

    Time frame: 3-6 months follow-up

  4. Intervention feasibility outcomes - Compliance

    percent of attended/performed educational modules.

    Time frame: 3-6 months follow-up

  5. Intervention feasibility outcomes - Farriers and facilitators

    Consecutive semi-structured patient and staff interviews will be performed until data saturation to explore barriers and facilitators for implementation.

    Time frame: 3-6 months follow-up

Secondary outcomes

  1. Study feasibility outcomes - Recruitment success

    Recruitment success: Time to assess the targeted the 50 patients for the feasibility study.

    Time frame: 3-6 months

  2. Study feasibility outcomes - Retention

    Number of recruited patients that successfully completed the study (pre- and post-assessment)

    Time frame: 3-6 months

  3. Study feasibility outcomes - Data collection:

    Percentage of missing data in outcome assessments.

    Time frame: 3-6 months

  4. Health related outcomes - self efficacy

    Change in self-efficacy from t0 to t1 and t2, assessed with the Pulmonary Rehabilitation Adapted Index of Self-Efficacy

    Time frame: 3- 6 months follow-up

  5. Health related outcomes - HRQoL

    Change in HRQOL from t0 to t1 and t2 assessed by the King's Brief Interstitial Lung Disease health status questionnaire

    Time frame: 3- 6 months follow-up

  6. Health related outcomes - functional status

    functional status assessed by six-minute walking test (routinely collected data)

    Time frame: from start to end of inpatient rehabilitation

  7. Health related outcomes - self-reported health status (VAS)

    Time frame: 3- 6 months follow-up

  8. Health related outcomes - Anxiety and Depression Score

    Self-reported anxiety and depression (Hospital Anxiety and Depression Scale)

    Time frame: 3- 6 months follow-up

  9. Health related outcomes - oxygen supplementation

    Supplemental oxygen needs for activity and at rest (routinely collected data)

    Time frame: 3- 6 months follow-up

  10. Health related outcomes - Re-hospitalization

    re-hospitalization (y/n)

    Time frame: 3- 6 months follow-up

  11. Health related outcomes - survival

    survival (y/n)

    Time frame: 3- 6 months follow-up

07

Study locations

1 of 2 sites recruiting
  • Department for Pulmonary Medicine, Allergology and Clinical Immunology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
    Bern, 3010, Switzerland
    Not yet recruiting
  • Center for Rehabilitation & Sports Medicine Inselspital and Berner Reha Zentrum, Bern University Hospital, University of Bern, Switzerland
    Heiligenschwendi, 3625, Switzerland
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Individual patient data for patients who signed the additional informed consent for further use of data may be shared upon request.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Aug 2027, 22 months after the start.

Of 41 interventional studies with no phase under Pulmonary Fibrosis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 81. This study's planned 22 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2026
First posted
Mar 9, 2026
StartActual
Oct 7, 2025
Primary completionEst.
Aug 2027
CompletionEst.
Aug 2027
Last update
Mar 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07457463
Collaborators
University of Zurich, ZHAW School of Health Professions, Institute of Physiotherapy
Responsible party
Sponsor
First posted
Mar 9, 2026
Start date
Oct 7, 2025
Primary completion
Aug 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Mar 9, 2026

Study contacts

Thimo Marcin, PhD
Contact
thimo.marcin@rehabern.ch
+41 33 244 3048
Thomas Franz Riegler, PhD
Contact
thomas.riegler@zhaw.ch
+41 (0) 58 934 64 06
Thimo Marcin, PHD
principal investigator · Center for Rehabilitation & Sports Medicine Inselspital and Berner Reha Zentrum, Bern University Hospital, University of Bern, Switzerland
Sabina Guler, MD
principal investigator · Department for Pulmonary Medicine, Allergology and Clinical Immunology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion